[HTML][HTML] Effectiveness of 2, 3, and 4 COVID-19 mRNA vaccine doses among immunocompetent adults during periods when SARS-CoV-2 Omicron BA. 1 and BA. 2/BA …
R Link-Gelles - MMWR. Morbidity and mortality weekly report, 2022 - cdc.gov
MMWR. Morbidity and mortality weekly report, 2022•cdc.gov
… a COVID-19–like illness § diagnosis among 10 states during December 18, 2021–June 10,
2022, to evaluate VE of 2, 3, and 4 doses of mRNA COVID-19 vaccines (BNT162b2 [Pfizer-BioNTech]
or mRNA-1273 [Moderna]) compared with no vaccination among adults without
immunocompromising conditions. VE against COVID-19–associated hospitalization 7–119
days and ≥120 days after receipt of dose 3 was 92% (95% CI = 91%–93%) and 85% (95% CI
= 81%–89%), respectively, during the BA.1 period, compared with 69% (95% CI = 58%–76%) …
2022, to evaluate VE of 2, 3, and 4 doses of mRNA COVID-19 vaccines (BNT162b2 [Pfizer-BioNTech]
or mRNA-1273 [Moderna]) compared with no vaccination among adults without
immunocompromising conditions. VE against COVID-19–associated hospitalization 7–119
days and ≥120 days after receipt of dose 3 was 92% (95% CI = 91%–93%) and 85% (95% CI
= 81%–89%), respectively, during the BA.1 period, compared with 69% (95% CI = 58%–76%) …
Little is known about COVID-19 vaccine effectiveness (VE) during the Omicron variant BA. 2/BA. 2.12. 2–predominant period or VE of a fourth COVID-19 vaccine dose in persons aged≥ 50 years.
cdc.gov
以上显示的是最相近的搜索结果。 查看全部搜索结果